Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Montgomery

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 15, 2019
Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samplesStefano Porcelli, Siegfried Kasper, Joseph Zohar, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 13, 2020
Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter studyMarkus Dold, Lucie Bartova, Gernot Fugger, et al.
International Clinical Psychopharmacology|November 7, 2015
The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre studyPeter Höfer, Alexandra Schosser, Raffaella Calati, et al.
Translational Psychiatry|February 19, 2020
A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotypingChiara Fabbri, Siegfried Kasper, Alexander Kautzky, et al.
International Clinical Psychopharmacology|May 11, 2010
5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorderMagali Noro, Irina Antonijevic, Carlos Forray, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 6, 2017
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistanceChiara Fabbri, Concetta Crisafulli, Raffaella Calati, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 13, 2022
Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic studyMarco Calabrò, Chiara Fabbri, Siegfried Kasper, et al.
The International Journal of Neuropsychopharmacology|June 4, 2018
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)Markus Dold, Lucie Bartova, Gernot Fugger, et al.
Journal of Affective Disorders|October 10, 2022
Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patternsVincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|October 20, 2025
Schizophrenia Genetics Modulates Clinical Depressive FeaturesAlessandro Serretti, Daniel Souery, Siegfried Kasper, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 15, 2019
Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samplesStefano Porcelli, Siegfried Kasper, Joseph Zohar, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 13, 2020
Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter studyMarkus Dold, Lucie Bartova, Gernot Fugger, et al.
International Clinical Psychopharmacology|November 7, 2015
The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment--a European multicentre studyPeter Höfer, Alexandra Schosser, Raffaella Calati, et al.
Translational Psychiatry|February 19, 2020
A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotypingChiara Fabbri, Siegfried Kasper, Alexander Kautzky, et al.
International Clinical Psychopharmacology|May 11, 2010
5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorderMagali Noro, Irina Antonijevic, Carlos Forray, et al.
European Archives of Psychiatry and Clinical Neuroscience|March 6, 2017
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistanceChiara Fabbri, Concetta Crisafulli, Raffaella Calati, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 13, 2022
Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic studyMarco Calabrò, Chiara Fabbri, Siegfried Kasper, et al.
The International Journal of Neuropsychopharmacology|June 4, 2018
Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)Markus Dold, Lucie Bartova, Gernot Fugger, et al.
Journal of Affective Disorders|October 10, 2022
Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patternsVincenzo Oliva, Giuseppe Fanelli, Siegfried Kasper, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|October 20, 2025
Schizophrenia Genetics Modulates Clinical Depressive FeaturesAlessandro Serretti, Daniel Souery, Siegfried Kasper, et al.
Pageof 12